tiprankstipranks
Advertisement
Advertisement

Imunon Expands At-The-Market Equity Offering Capacity

Story Highlights
  • Imunon expanded its at-the-market stock offering to $17 million on March 23, 2026.
  • The company continues using equity financing, signaling reliance on public markets and potential dilution.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Imunon Expands At-The-Market Equity Offering Capacity

Claim 55% Off TipRanks

The latest update is out from Imunon ( (IMNN) ).

On March 23, 2026, Imunon, Inc. filed a prospectus supplement to register an additional $7 million of common stock under its existing at-the-market offering program with H.C. Wainwright & Co., expanding the total amount covered to $17 million. The company had previously sold about $4.8 million of stock under this arrangement, indicating its continued use of equity issuance to support its capital needs and maintain financial flexibility for operations and strategic initiatives.

An aggregate of $17 million of shares is now registered under the at-the-market program, reflecting Imunon’s intention to keep this funding channel available as market conditions permit. This move underscores the company’s reliance on public equity markets for financing and may have implications for existing shareholders through potential future dilution as additional shares are sold over time.

The most recent analyst rating on (IMNN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Imunon stock, see the IMNN Stock Forecast page.

Spark’s Take on IMNN Stock

According to Spark, TipRanks’ AI Analyst, IMNN is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, sustained losses, and negative free cash flow) and a longer-term downtrend in technicals. Offsetting factors include constructive earnings-call updates (Phase III progress, regulatory milestone, and lower operating expenses), but near-term liquidity constraints and reliance on external capital remain key risks.

To see Spark’s full report on IMNN stock, click here.

More about Imunon

Imunon, Inc. is a publicly traded company that issues common stock as part of its capital-raising activities in the financial markets. The company utilizes at-the-market equity offering programs through investment banks to access incremental funding by selling newly issued shares into the open market.

Average Trading Volume: 45,328

Technical Sentiment Signal: Strong Sell

Current Market Cap: $9.76M

Find detailed analytics on IMNN stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1